Research map: Disproportionality analysis of off-label intravitreal bevacizumab in the FDA Adverse Event Reporting System database

Back to the article

Papers in this map

  1. Data Analysis · Hadley Wickham · 2016 · 12580 citations · Cited by this paper
  2. Intravitreal bevacizumab-related AEs identified in FAERS · 2026 · Cites this paper
  3. The real-world safety of lacosamide and perampanel in children: a disproportionality analysis of the FDA Adverse Event Reporting System · 2025 · Related
  4. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies · The Emerging Risk Factors Collaboration · 2010 · 5229 citations · Cited by this paper
  5. Development and validation of a MedDRA-based signal detection construct for drug-induced neurobehavioral impairment · 2026 · Related
  6. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration · The CATT Research Group · 2011 · 2683 citations · Cited by this paper
  7. Drug-induced intestinal obstruction: insights from the FDA Adverse Event Reporting System · 2026 · Related
  8. Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration · Robert L. Avery · 2006 · 1138 citations · Cited by this paper
  9. Drug interactions in rheumatoid arthritis: a disparity between electronic database prediction and real-world co-prescription with different large language models · 2026 · Related
  10. Data Mining of the Public Version of the FDA Adverse Event Reporting System · Toshiyuki Sakaeda · 2013 · 1057 citations · Cited by this paper
  11. Prevalence and predictors of prescribing errors in a primary care setting in Ghana · 2026 · Related
  12. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature · Khalil Ghasemi Falavarjani · 2013 · 995 citations · Cited by this paper
  13. Integration of pre‑existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer · 2026 · Related
  14. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials · David M. Brown · 2013 · 831 citations · Cited by this paper
  15. Drug recall, its frequencies and conclusion: a retrospective secondary analysis involving 2-year publicly available data from Nepal · 2025 · Related
  16. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial · Usha Chakravarthy · 2013 · 757 citations · Cited by this paper
  17. General practitioner–pharmacist collaboration to enhance deprescribing of psychotropics, sedatives, and anticholinergics among older polypharmacy patients in primary care: study protocol of a cluster-randomized controlled trial (PARTNER) · 2026 · Related
  18. Intravitreal Aflibercept for Diabetic Macular Edema · David M. Brown · 2015 · 624 citations · Cited by this paper
  19. Real-world pharmacovigilance study on neonatal congenital anomalies associated with maternal drug exposure using the FDA Adverse Event Reporting System · 2025 · Related
  20. Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders · Bernadette Biondi · 2019 · 603 citations · Cited by this paper
  21. How is AI developing in pharmacovigilance? · 2026 · Related
  22. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES) · Lihteh Wu · 2007 · 457 citations · Cited by this paper
  23. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD · Robert L. Avery · 2014 · 384 citations · Cited by this paper
  24. Age-Related Macular Degeneration Preferred Practice Pattern® · Christina J. Flaxel · 2019 · 362 citations · Cited by this paper
  25. Association of Off-label Drug Use and Adverse Drug Events in an Adult Population · Tewodros Eguale · 2015 · 261 citations · Cited by this paper
  26. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial · Laurent Kodjikian · 2013 · 260 citations · Cited by this paper
  27. A curated and standardized adverse drug event resource to accelerate drug safety research · Juan M. Banda · 2016 · 260 citations · Cited by this paper
  28. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement · Michele Fusaroli · 2024 · 245 citations · Cited by this paper
  29. Drug safety assessment in clinical trials: methodological challenges and opportunities · Sonal Singh · 2012 · 233 citations · Cited by this paper
  30. Cutis laxa: A review · David R. Berk · 2012 · 221 citations · Cited by this paper
  31. Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment · Anastasia Vladimirovna Poznyak · 2022 · 203 citations · Cited by this paper
  32. An Outbreak of Streptococcus Endophthalmitis After Intravitreal Injection of Bevacizumab · Roger A. Goldberg · 2012 · 156 citations · Cited by this paper
  33. Association Between Pre-hypertension and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Prospective Studies · Xiaofan Guo · 2013 · 152 citations · Cited by this paper
  34. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age‐related macular degeneration with bevacizumab or ranibizumab · Ângela M. Carneiro · 2011 · 151 citations · Cited by this paper
  35. Diabetes mellitus and diabetic foot ulcer: Etiology, biochemical and molecular based treatment strategies via gene and nanotherapy · Arokia Vijaya Anand Mariadoss · 2022 · 136 citations · Cited by this paper
  36. FDA Adverse Event Reporting System ( FAERS ) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS · Elizabeth Lake Potter · 2025 · 119 citations · Cited by this paper
  37. Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis · Manhong Xu · 2022 · 112 citations · Cited by this paper
  38. Intravitreal anti-VEGF agents and cardiovascular risk · Massimo Porta · 2019 · 102 citations · Cited by this paper
  39. Bevacizumab: Off-label use in ophthalmology · Salvatore Grisanti · 2007 · 90 citations · Cited by this paper

Source: OpenAlex (CC0)